E-LIB Suche - Ergebnisse für: Miles, David W.

1

Genetic markers of bevacizumab-induced hypertension:

Lambrechts, Diether ; Moisse, Matthieu ; Delmar, Paul...
Angiogenesis. , 2014

Link: https://doi.org/10.1007/..

2

Genetic variability of VEGF pathway genes in six randomized..:

de Haas, Sanne ; Delmar, Paul ; Bansal, Aruna T....
Angiogenesis. 17 (2014) 4 - p. 909-920 , 2014

Link: https://doi.org/10.1007/..

3

Safety of bevacizumab in metastatic breast cancer patients ..:

Cortés, Javier ; Caralt, Mireia ; Delaloge, Suzette...
European Journal of Cancer. 48 (2012) 4 - p. 475-481 , 2012

Link: https://doi.org/10.1016/..

4

Efficacy and safety of bevacizumab in combination with doce..:

Pivot, Xavier ; Schneeweiss, Andreas ; Verma, Shailendra...
European Journal of Cancer. 47 (2011) 16 - p. 2387-2395 , 2011

Link: https://doi.org/10.1016/..

5

Recent advances in systemic therapy. When HER2 is not the t..:

Miles, David W
Breast Cancer Research. 11 (2009) 4 - p. , 2009

Link: https://doi.org/10.1186/..

6

A phase II study of weekly docetaxel in patients with anthr..:

Ford, Hugo E. R. ; Yap, Yoon-Sim ; Miles, David W....
Cancer Chemotherapy and Pharmacology. 58 (2006) 6 - p. 809-815 , 2006

Link: https://doi.org/10.1007/..

7

Quality of Life in Women with Advanced Breast Cancer Treate..:

Twelves, Chris J. ; Miles, David W. ; Hall, Angela
Clinical Breast Cancer. 5 (2004) 3 - p. 216-222 , 2004

Link: https://doi.org/10.3816/..

8

Update on HER-2 as a target for cancer therapy: Herceptin i..:

Miles, David W
Breast Cancer Research. 3 (2001) 6 - p. , 2001

Link: https://doi.org/10.1186/..

9

Effect of c-erbB2 and estrogen receptor status on survival ..:

Miles, David W. ; Harris, William H. ; Gillett, Cheryl E...
International Journal of Cancer. 84 (1999) 4 - p. 354-359 , 1999

Link: https://doi.org/10.1002/..

10

The localization of the insulin-like growth factor receptor..:

Happerfield, Lisa C. ; Miles, David W. ; Barnes, Diana M....
The Journal of Pathology. 183 (1997) 4 - p. 412-417 , 1997

Link: https://doi.org/10.1002/..

11

Development and evaluation of a predictive model for the ef..:

Miles, David W ; Ross, Thomas ; Olley, June.
International Journal of Food Microbiology. 38 (1997) 2-3 - p. 133-142 , 1997

Link: https://doi.org/10.1016/..

12

p53 immunohistochemical staining and survival after adjuvan..:

Dublin, Edwin A. ; Miles, David W. ; Rubens, Robert D...
International Journal of Cancer. 74 (1997) 6 - p. 605-608 , 1997

Link: https://doi.org/10.1002/..

13

Diagnosis and management of malignant pleural effusion:

Miles, David W. ; Knight, Robert K.
Cancer Treatment Reviews. 19 (1993) 2 - p. 151-168 , 1993

Link: https://doi.org/10.1016/..

14

Mitomycin, ifosfamide and cisplatin in non-small-cell lung ..:

Currie, David C. ; Miles, David W. ; Drake, Jane S....
Cancer Chemotherapy and Pharmacology. 25 (1990) 5 - p. 380-381 , 1990

Link: https://doi.org/10.1007/..

15

Critical research gaps and translational priorities for the..:

Eccles, Suzanne A ; Aboagye, Eric O ; Ali, Simak...
https://www.repository.cam.ac.uk/handle/1810/292091. , 2013

Link: https://www.repository.c..